JP2020528878A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528878A5 JP2020528878A5 JP2019570445A JP2019570445A JP2020528878A5 JP 2020528878 A5 JP2020528878 A5 JP 2020528878A5 JP 2019570445 A JP2019570445 A JP 2019570445A JP 2019570445 A JP2019570445 A JP 2019570445A JP 2020528878 A5 JP2020528878 A5 JP 2020528878A5
- Authority
- JP
- Japan
- Prior art keywords
- ifn
- interferon
- cancer
- prodrug
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000014150 Interferons Human genes 0.000 claims 43
- 108010050904 Interferons Proteins 0.000 claims 43
- 229940079322 interferon Drugs 0.000 claims 43
- 239000000651 prodrug Substances 0.000 claims 23
- 229940002612 prodrug Drugs 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 102000006992 Interferon-alpha Human genes 0.000 claims 4
- 238000003776 cleavage reaction Methods 0.000 claims 4
- 230000007017 scission Effects 0.000 claims 4
- -1 IFN-δ Proteins 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 102100036464 Activated RNA polymerase II transcriptional coactivator p15 Human genes 0.000 claims 2
- 102000004225 Cathepsin B Human genes 0.000 claims 2
- 108090000712 Cathepsin B Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 101000713904 Homo sapiens Activated RNA polymerase II transcriptional coactivator p15 Proteins 0.000 claims 2
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 claims 2
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 claims 2
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 claims 2
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 claims 2
- 102100026720 Interferon beta Human genes 0.000 claims 2
- 102100026688 Interferon epsilon Human genes 0.000 claims 2
- 101710147309 Interferon epsilon Proteins 0.000 claims 2
- 102100022469 Interferon kappa Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 108090000467 Interferon-beta Proteins 0.000 claims 2
- 229910004444 SUB1 Inorganic materials 0.000 claims 2
- 208000003837 Second Primary Neoplasms Diseases 0.000 claims 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 2
- 230000027455 binding Effects 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000001794 hormone therapy Methods 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 108010080375 interferon kappa Proteins 0.000 claims 2
- 108700027921 interferon tau Proteins 0.000 claims 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 1
- 102100027995 Collagenase 3 Human genes 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 claims 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 claims 1
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 claims 1
- 101001011906 Homo sapiens Matrix metalloproteinase-14 Proteins 0.000 claims 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 claims 1
- 101000577874 Homo sapiens Stromelysin-2 Proteins 0.000 claims 1
- 101000577877 Homo sapiens Stromelysin-3 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 claims 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 claims 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102100030416 Stromelysin-1 Human genes 0.000 claims 1
- 102100028848 Stromelysin-2 Human genes 0.000 claims 1
- 102100028847 Stromelysin-3 Human genes 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 206010054094 Tumour necrosis Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762522564P | 2017-06-20 | 2017-06-20 | |
| US62/522,564 | 2017-06-20 | ||
| PCT/US2018/037982 WO2018236701A1 (en) | 2017-06-20 | 2018-06-18 | INTERFERON PRODRUCE FOR THE TREATMENT OF CANCER |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020528878A JP2020528878A (ja) | 2020-10-01 |
| JP2020528878A5 true JP2020528878A5 (cg-RX-API-DMAC10.html) | 2021-05-27 |
Family
ID=64737368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570445A Pending JP2020528878A (ja) | 2017-06-20 | 2018-06-18 | がん治療用インターフェロンプロドラッグ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200123227A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3641829A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2020528878A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20200015742A (cg-RX-API-DMAC10.html) |
| CN (1) | CN111050803A (cg-RX-API-DMAC10.html) |
| CA (1) | CA3067539A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018236701A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210130430A1 (en) | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| MX2020012251A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina-2 activables y metodos de uso de los mismos. |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| CA3136602A1 (en) | 2019-04-15 | 2020-10-22 | Qwixel Therapeutics Llc | Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer |
| BR112021022666A2 (pt) | 2019-05-14 | 2022-03-29 | Werewolf Therapeutics Inc | Frações de separação e seus métodos e uso |
| CN114341189A (zh) | 2019-06-12 | 2022-04-12 | 奥美药业有限公司 | 全新il-15前药及其应用 |
| AU2020316002B2 (en) * | 2019-07-25 | 2026-05-07 | The University Of Chicago | Compositions and methods comprising protease-activated therapeutic agents |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| AU2021205981A1 (en) | 2020-01-11 | 2022-07-14 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| US20240076355A1 (en) * | 2021-01-14 | 2024-03-07 | AskGene Pharma, Inc. | Interferon Prodrugs and Methods of Making and Using the Same |
| KR20230157448A (ko) * | 2021-03-16 | 2023-11-16 | 싸이톰스 테라퓨틱스, 인크. | 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법 |
| KR20240021943A (ko) * | 2021-06-18 | 2024-02-19 | 남미 테라퓨틱스, 인크. | 암의 치료에 사용하기 위한 마스킹된 유형 I 인터페론 (IFNα 및 IFNβ)을 포함하는 융합 단백질 조성물(들) 및 그의 방법 |
| EP4387987A2 (en) * | 2021-08-18 | 2024-06-26 | Werewolf Therapeutics, Inc. | Activatable inteferon polypeptides and methods of use thereof |
| US20240400633A1 (en) * | 2021-09-30 | 2024-12-05 | Orionis Biosciences, Inc. | Split human ifn-gamma and tnf-alpha constructs and uses thereof |
| WO2023060156A2 (en) * | 2021-10-08 | 2023-04-13 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| MX2024004301A (es) * | 2021-10-08 | 2024-04-26 | Cytomx Therapeutics Inc | Construcciones de citocinas activables y metodos combinados. |
| US20240067691A1 (en) * | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| WO2024186193A1 (ko) * | 2023-03-08 | 2024-09-12 | 인제대학교 산학협력단 | 국소적 방사선 치료에서 전신성 항암 치료를 위한 조성물 |
| KR20260026098A (ko) * | 2023-05-12 | 2026-02-25 | 리제너론 파아마슈티컬스, 인크. | 인터페론 수용체 길항제 및 이의 용도 |
| EP4750813A1 (en) * | 2023-07-25 | 2026-06-03 | TJ Biopharma (Shanghai) Co., Ltd. | Masked interferon fusion proteins and uses thereof |
| WO2025201363A1 (zh) * | 2024-03-27 | 2025-10-02 | 高雄医学大学 | 细胞因子阻断抗体及其应用 |
| WO2026158523A1 (en) * | 2025-01-24 | 2026-07-30 | Tj Biopharma (Hangzhou) Co., Ltd. | Masked multifunctional proteins |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL197568B1 (pl) * | 1997-12-19 | 2008-04-30 | Applied Research Systems | Kompleks zawierający IFN typu I oraz podjednostkę IFNAR, jego zastosowanie, cząsteczka DNA i wektor ją zawierający, komórka gospodarza transformowana wektorem, kompozycja farmaceutyczna, lek, zastosowanie IFNAR, zastosowanie IFN typu I i podjednostki IFNAR, sposób wytwarzania białka fuzyjnego oraz sposób przedłużania okresu trwałości IFN |
| US20040014652A1 (en) * | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
| EP2190861A4 (en) * | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| US20100189727A1 (en) * | 2008-12-08 | 2010-07-29 | Tegopharm Corporation | Masking Ligands For Reversible Inhibition Of Multivalent Compounds |
| US8399219B2 (en) * | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
| US11291721B2 (en) * | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
-
2018
- 2018-06-18 JP JP2019570445A patent/JP2020528878A/ja active Pending
- 2018-06-18 EP EP18820121.4A patent/EP3641829A4/en not_active Withdrawn
- 2018-06-18 CN CN201880053451.8A patent/CN111050803A/zh active Pending
- 2018-06-18 WO PCT/US2018/037982 patent/WO2018236701A1/en not_active Ceased
- 2018-06-18 CA CA3067539A patent/CA3067539A1/en active Pending
- 2018-06-18 US US16/624,648 patent/US20200123227A1/en not_active Abandoned
- 2018-06-18 KR KR1020207000744A patent/KR20200015742A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3053456T3 (en) | Interleukin-2-fc fusion proteins and methods of use | |
| US10182984B2 (en) | Targeted interferons demonstrate potent apoptotic and anti-tumor activities | |
| JP2024074801A5 (cg-RX-API-DMAC10.html) | ||
| Mertens et al. | Treatment of nasopharyngeal carcinoma in children and adolescents: definitive results of a multicenter study (NPC‐91‐GPOH) | |
| Ungerechts et al. | Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine | |
| JP2020530298A5 (cg-RX-API-DMAC10.html) | ||
| Cicchelero et al. | Intratumoural interleukin 12 gene therapy stimulates the immune system and decreases angiogenesis in dogs with spontaneous cancer | |
| Chester et al. | Engineering antibodies for clinical applications in cancer | |
| Iorgulescu et al. | Immunotherapy for glioblastoma: going viral | |
| JP2021500932A5 (cg-RX-API-DMAC10.html) | ||
| JP2006500009A5 (cg-RX-API-DMAC10.html) | ||
| EP1315742B1 (en) | Amino acid substitution mutants of interleukin 13 | |
| Touchefeu et al. | Radiovirotherapy: principles and prospects in oncology | |
| Larcombe-Young et al. | PanErbB-targeted CAR T-cell immunotherapy of head and neck cancer | |
| Öcal et al. | Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib | |
| Tojjari et al. | Exploring Glypican-3 as a molecular target in hepatocellular carcinoma: perspectives on diagnosis and precision immunotherapy strategies | |
| ATE521629T1 (de) | Matrixmetalloproteinase-11-impfstoff | |
| Yoshikawa et al. | Gene expression in response to anti-tumour intervention by polysaccharide-K (PSK) in colorectal carcinoma cells | |
| RU2020101640A (ru) | Пролекарство интерферона для лечения рака | |
| JP2024531338A (ja) | 活性化可能インターフェロンポリペプチド及びその使用方法 | |
| Boisgerault et al. | Oncolytic virotherapy for human malignant mesothelioma: recent advances | |
| Spitzweg | Gene therapy in thyroid cancer | |
| Tsai et al. | Enhancement of antitumor activity of gammaretrovirus carrying IL-12 gene through genetic modification of envelope targeting HER2 receptor: a promising strategy for bladder cancer therapy | |
| Santhosh et al. | Role of 18F-FDG PET/CT in the management of a case of autoimmune pancreatitis with extrapancreatic manifestations | |
| Johnson et al. | Intracranial response in patients with baseline brain metastases and extensive-stage small cell lung cancer treated with ifinatamab deruxtecan (I DXd) in the IDeate-Lung01 study |